Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00033748 · ClinicalTrials.gov registry record · Phase 2

Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver

A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
56
Enrollment target

NCT00033748 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 56 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00033748, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
56 participants
Enrollment target

Study Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have colorectal cancer that has spread to the liver.

Interventions

  • BIOLOGICAL monoclonal antibody 11D10 anti-idiotype
  • BIOLOGICAL monoclonal antibody 3H1 Alu Gel

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2001-12
Est. Completion 2010-06
Phase Phase 2

What the Registry Record Tells You About NCT00033748

The ClinicalTrials.gov registry entry for NCT00033748 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which monoclonal antibody 11D10 anti-idiotype is the first listed.

NCT00033748 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00033748 about?

NCT00033748 is a clinical study titled "Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have colorectal cancer that has spread to the liver.

What is the current status of trial NCT00033748?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2001-12. Estimated completion is 2010-06.

What interventions are being tested in trial NCT00033748?

The interventions under investigation include: monoclonal antibody 11D10 anti-idiotype (BIOLOGICAL), monoclonal antibody 3H1 Alu Gel (BIOLOGICAL).

Who is sponsoring clinical trial NCT00033748?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.